Anaphylaxis

December 2nd 2024

The FDA affirmed the planned NDA content and format for Anaphylm expected in Q1 2025, without requiring additional adult clinical trials before submission.

November 11th 2024

These data were explored to identify risk, recommendations, and guidelines related to vaccine-related allergic reactions such as anaphylaxis.

November 8th 2024

In recent findings presented at ACAAI 2024, patients, caregivers, and even emergency medical professionals were shown to face issues with regard to treatment of anaphylaxis reactions.

November 8th 2024

The Parental Self-efficacy in Managing Anaphylaxis (PSEMA) questionnaire was shown to be effective in assessing self-efficacy of parents in managing their childrens’ conditions.